Role of Neoadjuvent Radiotherapy in Locally Advanced Cancer Rectum

Status Not yet recruiting

Clinical Trial Summary

This is a retrospective study comparing neoadjuvent short course radiotherapy to conventional chemoradiation in locally advanced cancer rectum and the effect of both regimens in overall survival and disease free survival

Clinical Trial Description

Colorectal cancer is the third most common cancer diagnosed in the western world. In 2019 there were approximately 44180 new cases of rectal cancer diagnosed in the United states. Due to the close proximity of the rectum to pelvic structures and organs, the absence of a serious membrane surrounding the rectum and the restriction of the surgical view and access by the pelvic cavity, the locoregional recurrence rate in rectal cancer is relatively high after surgery alone. Neoadjuvent therapy rather than surgery followed by adjuvent therap has been the preferred approach world wide in treatment of rectal cancer since the 2004 publication of the seminal German CAO/ARO/AIO-94 study ,which compared preoperative with postoperative chemoradiation in 823 patients The use of neoadjuvent therapy is recommended for all newly diagnosed rectal adenocarcinoma with a clinical stage T3 or T4 based on trans rectal endoscopic ultrasound or pelvic MRI .Neoadjuvent therapy may comprise of either radiotherapy alone or in combination with chemotherapy, commonly prescribed chemotherapy agents include 5-fluorouracil and Oxaloplatin. Both short course radiotherapy (25 Gy in 5 fractions) and long course radiotherapy (50.4Gy in 28 fractions, conventionally fractionated therapy)can be applied as neoadjuvent radiotherapy. Several phase lll RCTs,including three large well-designed international RCTs have reported that short course neoadjuvent radiation treatment improves local control compared with surgery alone in patients with respectable rectal cancer. Also ,neoadjuvent chemoradiation with long course radiotherapy can be recommended for most patients with stage ll- lll rectal cancer with the aim of reducing the risk of local recurrence, for reducing rates of perioperative and post operative complications and in an attempt to avoid radical surgery with permanent colostomy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04814784
Study type	Observational
Source	Assiut University
Contact	Amany Sayed Abass
Phone	+201066756847
Email	amanysayed385@gmail.com
Status	Not yet recruiting
Phase
Start date	March 31, 2021
Completion date	October 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05081024` - Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
Not yet recruiting	`NCT04090450` - Optimisation of Radiotherapy in Rectal Cancer (ORREC)
Active, not recruiting	`NCT03300544` - Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer	Phase 1
Recruiting	`NCT06050447` - Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
Terminated	`NCT02233595` - Evaluation of Rectal Cancer Treatment Response Using PET/MRI
Completed	`NCT02935309` - Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma	Phase 1
Terminated	`NCT01887509` - Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology	N/A
Recruiting	`NCT05746195` - Optimization of Adaptive Text Messages for Cancer Survivors (OATS II)	N/A
Active, not recruiting	`NCT03365882` - S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery	Phase 2
Completed	`NCT02314182` - GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis	Phase 3
Completed	`NCT02393755` - Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer	Phase 1/Phase 2
Recruiting	`NCT04441580` - Assessing the Additional Neoplasia Yield of Computer-aided Colonoscopy in a Screening Setting	N/A
Terminated	`NCT03527784` - Prestoma-Trial for Parastomal Hernia Prevention	N/A
Completed	`NCT00855946` - Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy	N/A
Recruiting	`NCT02107105` - Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
Not yet recruiting	`NCT06328361` - Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer	N/A
Active, not recruiting	`NCT03436563` - M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability	Phase 1/Phase 2
Recruiting	`NCT05482516` - Evaluating Novel Therapies in ctDNA Positive GI Cancers	Phase 3
Completed	`NCT02368886` - Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer	Phase 2
Active, not recruiting	`NCT02688712` - ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer	Phase 2